Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
J G StorosumA W Broekmans

Abstract

The original data from the placebo-arms and the tricyclic-arms of all parallel randomized controlled three-arm studies, which had been conducted in the period 1979-1991 for a drug under development in order to obtain marketing authorization for the indication major depression, were included in a meta-analysis. Thirty-two placebo-controlled studies including 4314 patients were analyzed. The intention to treat analysis resulted in 46% responders (at least 50% improvement on the Hamilton Depression Rating Scale) in the tricyclic antidepressant group and 31% in the placebo-group (CI(95%-difference) 11.5-17.1%). The number needed to treat for responders was 7 (CI(95%) 5-8). In 10 out of 32 studies, a statistically significant difference in favor of tricyclic antidepressant compared to placebo was found for responders. The responder rate in the placebo-group varied from 6 to 52%. We conclude that tricyclic antidepressants are efficacious in the short-term treatment of major depression. However, the magnitude of the effect is rather modest. Because 69% of the placebo-controlled studies with a tricyclic antidepressant did not show a statistically significant difference in favor of tricyclic antidepressant and the placebo rate varied co...Continue Reading

References

Jun 30, 1988·The New England Journal of Medicine·A LaupacisR S Roberts
Aug 11, 1994·The New England Journal of Medicine·K J Rothman, K B Michels
Nov 7, 1998·BMJ : British Medical Journal·D G Altman
Nov 1, 1958·The American Journal of Psychiatry·R KUHN
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Oct 28, 2009·Der Nervenarzt
Oct 18, 2011·Der Nervenarzt·S LeuchtJ M Davis
Nov 21, 2008·European Archives of Psychiatry and Clinical Neuroscience·Hans Jürgen Möller
Oct 29, 2011·European Archives of Psychiatry and Clinical Neuroscience·Thomas C BaghaiUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
Apr 20, 2002·Lancet·John A LewisBarbara van Zwieten-Boot
Jun 20, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·David HackettEliseo Salinas
Jan 22, 2002·International Clinical Psychopharmacology·G B CassanoUNKNOWN AMIMAJOR Group
Jan 27, 2006·International Clinical Psychopharmacology·Stuart A Montgomery
Oct 6, 2007·International Clinical Psychopharmacology·Stuart A MontgomeryMichael E Thase
May 15, 2003·BMC Psychiatry·Emily J WangBarbara L Parry
May 17, 2011·Philosophy, Ethics, and Humanities in Medicine : PEHM·John M DavisStefan Leucht
Dec 5, 2006·CNS Drugs·Michael Zupancic, Christian Guilleminault
Aug 25, 2005·Paediatric Drugs·Graham J EmslieMaryse Ruberu
Feb 3, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Stefan LeuchtJohn M Davis
Jul 13, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Malcolm Lader
Jun 17, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·S HenrikssonG Isacsson
Dec 20, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hendrik G RoozenAd J F M Kerkhof
Sep 16, 2006·Biometrical Journal. Biometrische Zeitschrift·Tim Friede, Meinhard Kieser
Jan 3, 2012·Journal of Affective Disorders·Taro SuwaToshiya Murai
Jul 25, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive Disorders
Oct 27, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S H Kennedy, R Emsley
May 5, 2007·The International Journal of Neuropsychopharmacology·Jean Pierre Olié, Siegfried Kasper
Jun 19, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Christine Gispen-de WiedFernando de Andres-Trelles
Jul 23, 2003·Journal of Psychopharmacology·G M Goodwin, UNKNOWN Consensus Group of the British Association for Psychopharmacology
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Claudia LeuchtStefan Leucht
Nov 11, 2005·Clinical Trials : Journal of the Society for Clinical Trials·Mark C SimmondsSimon G Thompson
Mar 1, 2002·Expert Review of Neurotherapeutics·Jonathan Sporn, Dennis Charney
Jul 16, 2008·Journal of Clinical Psychopharmacology·Martin M Katz
Apr 25, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN WFSBP Task Force on Unipolar Depressive Disorders
Dec 14, 2002·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders
Jul 4, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Hans-Jürgen Möller
Nov 20, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Julien Mendlewicz
Nov 29, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·H-J MöllerUNKNOWN European Psychiatric Association
Oct 18, 2007·Expert Review of Neurotherapeutics·Paolo MannelliAshwin A Patkar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.